Editorial review
Educational content is reviewed for source quality, clinical boundaries, and readability. It is not medical advice; confirm care decisions with a licensed clinician.
Prior Authorization Rarely Applies to Compounded Ketamine Tablets
Most health insurers do not run a prior authorization process for compounded oral ketamine tablets, because the tablets are not an FDA-approved treatment for depression. Prior authorization, often shortened to PA, is a health plan's requirement that a prescriber submit documentation before the plan agrees to pay for a drug or service. Insurers reserve PA pathways for products with an approved indication, a standardized dosing protocol, and a defined safety monitoring program, and compounded ketamine tablets currently have none of those on file with most plans.
Quick Answer
Insurers generally will not run a standard prior authorization for compounded oral ketamine tablets, because the FDA has not approved ketamine tablets for depression, so most plans treat the prescription as an off-label, self-pay treatment. Prior authorization does apply to esketamine (Spravato), the FDA-approved nasal spray for treatment-resistant depression, which requires documented failure of at least two antidepressants plus enrollment in its Risk Evaluation and Mitigation Strategy (REMS) program. When a plan does agree to cover oral ketamine, it's usually through a medical exception or single-case agreement, not a routine PA form.
Why Only Esketamine Goes Through Standard Prior Authorization
The FDA approved esketamine (Spravato) in 2019 for treatment-resistant depression in adults and in 2020 for depressive symptoms with suicidal ideation. That approval gives esketamine a defined indication, dosing schedule, and REMS monitoring requirement that a plan's PA reviewer can check a claim against.
Oral ketamine tablets, troches, and sublingual formulations are compounded by pharmacies and prescribed off-label, meaning a licensed prescriber is using clinical judgment to treat a condition the drug was not originally approved for. Racemic ketamine's use for depression is supported mainly by smaller controlled trials rather than the large Phase 3 studies the FDA requires for approval, a distinction the National Institute of Mental Health (NIMH) reflects in how it describes ketamine's current evidence base for depression. Because there is no FDA-approved indication for oral ketamine tablets, most insurers have no PA pathway to route a claim through, and the default outcome is a denial coded as "not medically necessary" or "experimental/investigational."
This is also why ketamine tablet prescription laws focus on state pharmacy and prescribing rules rather than insurance mandates: coverage isn't the legal question, medical necessity under FDA-approved-use language is.
Compare tablet options
Review tablets versus troches, IV infusion, and other routes before deciding what to ask.
Compare optionsREMS Requirements Apply to Spravato, Not Tablets
If your plan cites a REMS program in a denial letter, confirm which drug the letter references. The Spravato REMS applies to esketamine nasal spray administered under direct observation in a certified healthcare setting. Compounded oral ketamine tablets are not enrolled in any REMS program because they are not FDA-approved, so a REMS citation on a tablet claim usually signals plan confusion worth flagging to your prescriber's billing staff.
What Happens If You Submit a Ketamine Tablet Claim Anyway
Prescriber writes the prescription
A licensed prescriber documents the off-label rationale and sends the prescription to a compounding pharmacy, since oral ketamine tablets are not manufactured by a standard commercial supplier.
Pharmacy attempts to bill or issues a cash-pay invoice
Many compounded medications lack a standard National Drug Code (NDC), so pharmacy systems often cannot process an insurance claim at the counter and default to cash pay.
You submit a claim or superbill for reimbursement
If you pay out of pocket, you can request an itemized superbill from the clinic and pharmacy and submit it to your plan for out-of-network reimbursement consideration.
The plan reviews and typically denies
Reviewers check the claim against FDA-approved indications; without one, most plans deny the claim as investigational rather than opening a PA review.
You can appeal, but success is uncommon
An appeal or peer-to-peer review lets your prescriber argue medical necessity, but plans generally require randomized controlled trial evidence that oral ketamine for depression does not yet have at FDA-approval scale.
Key Takeaway
Treat oral ketamine tablets as a self-pay treatment unless your prescriber's office tells you otherwise in writing. Budgeting for out-of-pocket cost up front avoids a surprise denial after you've already started a course of tablets.
What to Do Instead of Waiting on Prior Authorization
- Ask your prescriber's clinic for a cash-pay price quote before your first fill
- Request an itemized superbill you can submit for out-of-network reimbursement
- Check whether you can use FSA or HSA funds to offset the cost
- Confirm whether Medicare covers any part of the prescribing visit or labs
- Confirm whether Medicaid covers any part of the visit in your state
- Ask the compounding pharmacy about its state licensing before you fill
Where the Real Cost Questions Live
Because prior authorization mostly doesn't apply, the cost conversation shifts to what you can offset outside a PA process. Start with whether you can use FSA or HSA funds for ketamine tablets, since these accounts don't require the same FDA-approved-indication test a health plan does. Then check does Medicare cover ketamine tablets and does Medicaid cover oral ketamine tablets for your specific situation, since coverage of the prescribing visit and lab monitoring sometimes differs from coverage of the tablets themselves. Before you fill a prescription, it also helps to review compounded ketamine tablets pharmacy questions so you know what to ask the pharmacy about sourcing, stability, and dosage strength.
This is educational information, not medical or insurance advice. Coverage rules vary by plan and change over time, so confirm your specific plan's language with your insurer and discuss any off-label treatment plan, including cost, with a licensed prescriber before you begin.
Get Help Navigating a Legitimate Prescription
Understand the proper channels for evaluation and prescribing before you budget for tablets or troches.
Frequently Asked Questions
It's uncommon. Some plans will cover the prescribing visit or required lab monitoring even when they won't cover the tablets themselves, since compounded ketamine for depression lacks an FDA-approved indication. Ask your plan directly rather than assuming either outcome.
Spravato (esketamine) has FDA approval for treatment-resistant depression, so plans can run a standard PA review checking for documented antidepressant failures and REMS enrollment. Oral ketamine tablets are compounded and prescribed off-label, so there's usually no approved-indication framework for a plan to review against.
You can file an appeal, and your prescriber can request a peer-to-peer review to argue medical necessity. Success is uncommon because most plans require large-scale controlled trial evidence that oral ketamine for depression does not yet have at FDA-approval level.
Sometimes partially, through out-of-network reimbursement if you submit an itemized superbill, but many plans still deny the tablet cost itself as investigational. It's worth submitting a claim if you've already paid, since some plans do reimburse associated visit or lab costs even when they deny the medication line.
Share
Related Reading
Contact Ketamine Tablet
Send corrections, provider questions, or advertising inquiries.